Sera Prognostics Stock Price, News & Analysis (NASDAQ:SERA) $1.89 -0.10 (-5.03%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$1.85▼$2.0450-Day Range$1.65▼$2.4052-Week Range$1.10▼$4.25Volume9,846 shsAverage Volume395,323 shsMarket Capitalization$59.23 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Sera Prognostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside45.5% Upside$2.75 Price TargetShort InterestHealthy1.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.16) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector458th out of 949 stocksMedical Laboratories Industry11th out of 22 stocks 3.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.75, Sera Prognostics has a forecasted upside of 45.5% from its current price of $1.89.Amount of Analyst CoverageSera Prognostics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.84% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 0.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next 2.6 News and Social Media Coverage News SentimentSera Prognostics has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sera Prognostics this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have not sold or bought any company stock.Percentage Held by Insiders15.60% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.46% of the stock of Sera Prognostics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($1.16) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sera Prognostics Stock (NASDAQ:SERA)Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More SERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Stock News HeadlinesNovember 22, 2023 | finance.yahoo.comSERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCENovember 12, 2023 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call TranscriptNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 12, 2023 | investing.comEarnings call: Sera Prognostics Reports Q3 FY2023 Results, Focuses on Revenue Growth and Expense ManagementNovember 9, 2023 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | morningstar.comSera Prognostics Inc Class A SERANovember 8, 2023 | benzinga.comSera Prognostics: Q3 Earnings InsightsNovember 8, 2023 | msn.comSera Prognostics GAAP EPS of -$0.23 beats by $0.10, revenue of $0.04MNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 8, 2023 | finance.yahoo.comSera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ...November 8, 2023 | finance.yahoo.comSERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTSOctober 25, 2023 | finance.yahoo.comSera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023October 10, 2023 | msn.comWhy You Should Bet on These 5 Top-Ranked Stocks With Rising P/ESeptember 21, 2023 | finance.yahoo.comSERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023August 31, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAugust 30, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAugust 16, 2023 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | msn.comCitigroup Maintains Sera Prognostics Inc (SERA) Neutral RecommendationAugust 9, 2023 | finance.yahoo.comSERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTSAugust 9, 2023 | finance.yahoo.comSera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue EstimatesJuly 31, 2023 | finance.yahoo.comSera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023June 28, 2023 | fool.comSera Prognostics (NASDAQ: SERA)June 8, 2023 | msn.comSera Prognostics: Buy The PreTRM MoatMay 25, 2023 | marketwatch.comSera Prognostics Reduces Headcount to Cut Costs in Optimization StrategyMay 25, 2023 | finance.yahoo.comSera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and RevenueMay 15, 2023 | msn.comSera Prognostics CEO Critchfield to step down in JuneMay 15, 2023 | finance.yahoo.comSera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEOSee More Headlines Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside+45.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,190,000.00 Net Margins-11,534.24% Pretax Margin-11,534.24% Return on Equity-44.04% Return on Assets-37.26% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual Sales$270,000.00 Price / Sales219.38 Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book0.78Miscellaneous Outstanding Shares31,340,000Free Float26,448,000Market Cap$59.23 million OptionableNot Optionable Beta0.29 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Evguenia Lindgardt M.B.A. (Age 49)Interim President, CEO & Director Comp: $37.5kDr. Gregory C. Critchfield M.D. (Age 70)M.S., Executive Director Comp: $790.74kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Austin AertsChief Financial Officer??Dr. John J. Boniface Ph.D. (Age 61)Chief Scientific Officer Comp: $386.69kMr. Robert G. Harrison (Age 57)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 44)General Counsel Comp: $410.75kDr. Paul Kearney Ph.D. (Age 55)Chief Data Officer More ExecutivesKey CompetitorsDermTechNASDAQ:DMTKEnzo BiochemNYSE:ENZPersonalisNASDAQ:PSNLCentogeneNASDAQ:CNTGMDxHealthNASDAQ:MDXHView All CompetitorsInsiders & InstitutionsSanders Morris Harris LLCBought 81,933 shares on 10/13/2023Ownership: 1.423%Sanders Morris Harris LLCBought 81,933 shares on 10/5/2023Ownership: 1.423%Robert Gardner HarrisonSold 5,000 sharesTotal: $16,150.00 ($3.23/share)View All Insider TransactionsView All Institutional Transactions SERA Stock Analysis - Frequently Asked Questions Should I buy or sell Sera Prognostics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks. What is Sera Prognostics' stock price target for 2024? 2 brokers have issued 12-month price targets for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts. How have SERA shares performed in 2023? Sera Prognostics' stock was trading at $1.26 at the beginning of 2023. Since then, SERA shares have increased by 50.0% and is now trading at $1.89. View the best growth stocks for 2023 here. When is Sera Prognostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our SERA earnings forecast. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.17. The company earned $0.02 million during the quarter, compared to analyst estimates of $0.08 million. Sera Prognostics had a negative trailing twelve-month return on equity of 44.04% and a negative net margin of 11,534.24%. When did Sera Prognostics IPO? (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (1.42%) and Sanders Morris Harris LLC (1.42%). Insiders that own company stock include Benjamin Jackson, John J Boniface and Robert Gardner Harrison. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SERA) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.